Literature DB >> 29797351

Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.

Michael Sommerauer1,2, Allan K Hansen1, Peter Parbo1, Tatyana D Fedorova1, Karoline Knudsen1, Yoon Frederiksen3, Adjmal Nahimi1, Michael T Barbe2, David J Brooks1,4,5, Per Borghammer1.   

Abstract

Reduced noradrenaline levels have been reported to occur in the motor cortices of PD patients postmortem. Imaging techniques have recently become available to specifically study noradrenergic terminal function in vivo using PET. The objective of this study was to evaluate cortical 11 C-MeNER binding in PD patients. Thirty PD patients and 12 healthy control subjects comparable in age, sex, and cognitive performance underwent PET imaging with 11 C-MeNER, a specific ligand of the noradrenaline transporter. Cortical noradrenaline transporter binding was compared at a voxel level using Statistical Parametric Mapping, whereas cortical thickness was assessed using FreeSurfer software with MRI. PD patients showed reduced 11 C-MeNER binding in the primary motor cortex unrelated to cortical thickness; other cortical regions did not differ between groups. In a subgroup analysis, patients with higher Hoehn & Yahr stage exhibited more pronounced 11 C-MeNER binding reductions. Loss of cortical noradrenergic projections to the primary motor cortex occurs in PD associated with disease stage.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; motor cortex; noradrenaline

Mesh:

Substances:

Year:  2018        PMID: 29797351     DOI: 10.1002/mds.27411

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.

Authors:  Elisa Schmidt; Christian Schinke; Michael Rullmann; Julia Luthardt; Georg-Alexander Becker; Sarah Haars; Muriel Stoppe; Donald Lobsien; Karl-Titus Hoffmann; Osama Sabri; Swen Hesse; Florian Then Bergh
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

Review 2.  The Noradrenergic System in Parkinson's Disease.

Authors:  Elena Paredes-Rodriguez; Sergio Vegas-Suarez; Teresa Morera-Herreras; Philippe De Deurwaerdere; Cristina Miguelez
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

3.  Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation.

Authors:  Maira Ayaz; Fareeha Anwar; Uzma Saleem; Irum Shahzadi; Bashir Ahmad; Ali Mir; Tariq Ismail
Journal:  ACS Omega       Date:  2022-04-20

4.  Noradrenaline and Movement Initiation Disorders in Parkinson's Disease: A Pharmacological Functional MRI Study with Clonidine.

Authors:  Marion Criaud; Chloé Laurencin; Alice Poisson; Elise Metereau; Jérôme Redouté; Stéphane Thobois; Philippe Boulinguez; Bénédicte Ballanger
Journal:  Cells       Date:  2022-08-25       Impact factor: 7.666

Review 5.  Imaging of Motor Cortex Physiology in Parkinson's Disease.

Authors:  Roxana G Burciu; David E Vaillancourt
Journal:  Mov Disord       Date:  2018-10-02       Impact factor: 10.338

6.  Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.

Authors:  Cheng Zhou; Tao Guo; JingJing Wu; Linbo Wang; Xueqin Bai; Ting Gao; Xiaojun Guan; Luyan Gu; Peiyu Huang; Min Xuan; Quanquan Gu; Xiaojun Xu; Baorong Zhang; Wei Cheng; Jianfeng Feng; Minming Zhang
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.